Top

World Journal of Urology

Published in:

01-10-2019 | Topic Paper

Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)

Authors: Jean Carlo F. Datovo, Wilmar Azal Neto, Gustavo B. Mendonça, Danilo L. Andrade, Leonardo O. Reis

Published in: World Journal of Urology | Issue 10/2019

Abstract

Purpose

To evaluate the underexplored context of cystoscopy adherent versus non-adherent patients in the follow-up of urothelial high-risk non-muscle-invasive bladder cancer (NMIBC).

Methods

We performed a retrospective study (2005–2016) that evaluated patients´ demographical characteristics, histopathological data, recurrence, progression and cancer-specific mortality between adherent and non-adherents patients in the first 3 years of a proposed cystoscopy protocol.

Results

Among the 198 included patients, comparing cystoscopy non-adherent (n = 36, 18%) and adherent patients (n = 162, 82%), there was no demographic or histopathological differences; the rates of disease recurrence, progression and cancer-specific mortality were 15 (41.7%) versus 68 (42.2%), p = 0.58; 12 (33.3%) versus 28 (17.9%), p = 0.014 and 4 (11.1%) versus 19 (11.7%), p = 0.98, respectively. Cystoscopy non-adherence was associated with an inferior number of urinary cytology (p < 0.001) and 2.33 HR for cancer progression, p = 0.014, (95% CI 1.18–4.59).

Conclusions

Non-adherence to follow-up cystoscopy in NMIBC is associated with more than twice progression risk. Future studies are needed to confirm our results and correlate cystoscopy non-adherence to other covariates.

Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N et al (2013) ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63:4–15CrossRef

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96–108CrossRef

Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95:588–597CrossRef

Power NE, Izawa J (2016) Comparison of guidelines on non-muscle invasive bladder cancer. (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer 2:27–36CrossRef

Springer (2010) AJCC cancer staging manual, 7th edn. Springer, New York

Eble JSG, Epstein J, Sesterhenn I (2004) The world health organization classification of tumors of the urinary system and male genital system. IARC Press, Lyon

Ferreira U, Matheus WE, Azal Neto W, Souza MA, Fernandes RC, Calado BN et al (2017) Multicenter analysis of the oncological positivity on restaging resection (Re-Turbt) of urothelial non-muscle-invasive bladder cancer. ARC J Urol 2:25–30. https://doi.org/10.20431/2456-060X.0202004 CrossRef

Chang SS et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196:1021–1029CrossRef

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRef

10.

Woldu SL, Bagrodia A, Lotan Y (2017) Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 119(3):371–380CrossRef

11.

Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F, Houédé N, Larré S, Pignot G, Puech P, Roumiguié M, Xylinas E, Méjean A (2016) CCAFU french national guidelines 2016–2018 on bladder cancer. Prog Urol 27(Suppl 1):S67–S91CrossRef

12.

van Rhijn BW, Burger M (2016) Bladder cancer: low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol 13(10):570–571CrossRef

13.

Siddins MT, Wong VV, Fitzgerald JT, Bamberg LJ (2011) Challenges in non-muscle invasive bladder cancer: lessons from a regional review. ANZ J Surg 81:889–894CrossRef

14.

Lotan Y, Svatek RS, Malats N (2008) Screening for bladder cancer: a perspective. World J Urol 26:13–18CrossRef

15.

Roobol MJ, Bangma CH, el Bouazzaoui S, Franken-Raab CG, Zwarthoff EC (2010) Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol Oncol 28:686–690CrossRef

16.

Reis LO, Moro JC, Ribeiro LF, Voris BR, Sadi MV (2016) Are we following the guidelines on non-muscle invasive bladder cancer? Int Braz J Urol 42:22–28CrossRef

17.

Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J et al (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60:484–492CrossRef

18.

Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41:523–531CrossRef

19.

Burger M, Grossman HB, Droller M et al (2013) Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 64:846–854CrossRef

20.

Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461CrossRef

Title: Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)
Authors: Jean Carlo F. Datovo
Wilmar Azal Neto
Gustavo B. Mendonça
Danilo L. Andrade
Leonardo O. Reis
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 10/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02697-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2019

Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer

The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

Superselective vesical artery embolization in the management of intractable hematuria secondary to hemorrhagic cystitis

Oncological long-term outcome of whole gland HIFU and open radical prostatectomy: a comparative analysis

Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa

Association of training level and outcome of software-based image fusion-guided targeted prostate biopsies